{"id":19294,"date":"2018-05-18T10:46:51","date_gmt":"2018-05-18T08:46:51","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=19294"},"modified":"2022-03-10T05:50:54","modified_gmt":"2022-03-10T04:50:54","slug":"may-18-2018-dermapharm-holding-se-publishes-q1-2018-report","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/may-18-2018-dermapharm-holding-se-publishes-q1-2018-report\/","title":{"rendered":"<span id=\"2018\" class=\"Postdate\">May 18, 2018<\/span> | Dermapharm Holding SE publishes Q1 2018 report"},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;Zeile&#8221; make_fullwidth=&#8221;off&#8221; use_custom_width=&#8221;off&#8221; width_unit=&#8221;on&#8221; use_custom_gutter=&#8221;off&#8221; custom_padding=&#8221;||0px|&#8221; padding_mobile=&#8221;off&#8221; allow_player_pause=&#8221;off&#8221; parallax=&#8221;off&#8221; parallax_method=&#8221;off&#8221; make_equal=&#8221;off&#8221; parallax_1=&#8221;off&#8221; parallax_method_1=&#8221;off&#8221; parallax_2=&#8221;off&#8221; parallax_method_2=&#8221;off&#8221; column_padding_mobile=&#8221;on&#8221;][et_pb_column type=&#8221;1_2&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<style>\n.zur\u00fcckbutton:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #00225f;\n    margin-right: 7px;\n}\n.zur\u00fcckbutton:hover:before {\n    display: inline-block;\n    font-family: \"ETmodules\";\n    content: \"4a\";\n    color: #d85710;\n    margin-right: 7px;\n}\n<\/style>\n<h1 style=\"text-align: justify;\">Corporate news<\/h1>\n<p> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243;][et_pb_image admin_label=&#8221;Bild&#8221; src=&#8221;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8221; show_in_lightbox=&#8221;off&#8221; url_new_window=&#8221;off&#8221; use_overlay=&#8221;off&#8221; animation=&#8221;off&#8221; sticky=&#8221;off&#8221; align=&#8221;right&#8221; force_fullwidth=&#8221;off&#8221; always_center_on_mobile=&#8221;on&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<h1>Dermapharm Holding SE publishes Q1 2018 report <\/h1>\n<ul>\n<li>Revenues increased by 16.4% to EUR 137.5 million <\/li>\n<li>Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% <\/li>\n<li>International presence continued to expand with sales subsidiary in Italy <\/li>\n<li>Integration of Strathmann and Trommsdorff on schedule<\/li>\n<\/ul>\n<p><strong>Gr\u00fcnwald, May 18, 2018<\/strong> \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading producer of patent-free branded pharmaceuticals for select therapeutic areas in Germany with a growing international presence, published its report for the first three months of 2018 today, having increased its revenues by 16.4% to EUR 137.5 million (prior-year quarter: EUR 118.1 million). Earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off costs of EUR 0.7 million in connection with IPO preparations, were EUR 36.2 million, 25.3% higher than in the same quarter last year (EUR 28.9 million). The adjusted EBITDA margin was 26.3%, 1.8 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 35.5 million while the unadjusted EBITDA margin was 25.8%. <\/p>\n<p>Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, comments: \u201cThe first quarter of 2018 was characterized by our three-pillar strategy of in-house product development, internationalization and successful acquisitions. Together with the integration of Strathmann and Trommsdorff, we were able to expand our portfolio to include over-the-counter top sellers such as Keltican\u00ae forte, Tromcardin\u00ae complex and Ebenol\u00ae and at the same time acquire very promising prescription products for our core therapeutic areas. This has strengthened the share of branded therapeutics in our overall portfolio and reduced our dependence on direct health insurance discount contracts. Establishing mibe pharma Italia Srl in Bolzano in the first quarter was another important step in expanding our international presence and opening up the promising Italian market for our products.\u201d <\/p>\n<p>Revenues in the segment \u201cBranded Pharmaceuticals and Other Healthcare Products\u201d increased by 43.0% to EUR 79.5 million (prior-year quarter: EUR 55.6 million). The adjustment for one-off costs in connection with the IPO preparation relates entirely to this segment. Therefore, adjusted EBITDA in this segment increased by 26.4% to EUR 34.5 million, the unadjusted EBITDA increased by 23.8% to EUR 33.8 million (prior-year quarter: EUR 27.3 million). The increase is due in large part to positive gross profit development along with reductions in expenditures for discounts from direct contracts with health insurance companies and in materials costs. The acquisitions of the Strathmann Group and the Trommsdorff Group were also included in the consolidation of this segment for the first time. As a result of this first-time consolidation, the segment\u2019s EBITDA margin of 43.3% (adjusted) resp. 42.4% (unadjusted) was down from the prior-year quarter (49.1%). The integration of the two companies is proceeding according to plan and the Management Board expects further synergy effects in the Group for the future, which will have a positive impact on the individual margins. <\/p>\n<p>In the \u201cParallel Import Business\u201d segment, revenues fell by 7.2% to EUR 58.0 million in the reporting period (prior-year quarter: EUR 62.5 million). This decline was mainly due to the concentration on highmargin yet small-volume preparations. The German parallel import market is dominated by three very large-volume products, which achieve only very low margins due to the current market concentration on a few wholesalers in a few countries. Dermapharm therefore only made small purchases of these preparations in the first quarter of 2018, but expects improved margins already in the course of the current second quarter of 2018 due to new wholesalers in more European countries, setting the stage an increasing revenue dynamic in the Parallel Import Business in the coming quarters. EBITDA for the Parallel Import Business increased significantly in the first quarter by 68.8% to EUR 2.7 million (prioryear quarter: EUR 1.6 million). Dermapharm achieved this by optimizing its product portfolio, increasing the gross profit margin through demand-oriented purchasing and constant cost optimization in all areas. The EBITDA margin in Parallel Imports increased accordingly from 2.6% in the prior-year quarter to 4.7%. <\/p>\n<p>With the positive business development in the first quarter of 2018 and assuming unchanged conditions, the Management Board confirms its full-year forecast of revenue growth of 20 to 25% and an improvement in EBITDA of 22 to 27% over fiscal year 2017. <\/p>\n<p>The complete quarterly report is available as of today online at ir.dermapharm.com. <\/p>\n<p>Key financial figures for Q1 2018 year-on-year <\/p>\n<table class=\"tableizer-table\">\n<thead>\n<tr class=\"tableizer-firstrow\">\n<th>in EUR millions <\/th>\n<th>Q1\/2018 <\/th>\n<th>Q1\/2017 <\/th>\n<th>Change <\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Group sales <\/td>\n<td>137.5 <\/td>\n<td>118.1 <\/td>\n<td>+ 16.4% <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and Other Health Products <\/td>\n<td>79.5 <\/td>\n<td>55.6 <\/td>\n<td>+ 43.0% <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>58.0 <\/td>\n<td>62.5 <\/td>\n<td>&#8211; 7.2% <\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group holding <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 Group EBITDA <\/td>\n<td>36.2 <\/td>\n<td>28.9 <\/td>\n<td>+ 25.3% <\/td>\n<\/tr>\n<tr>\n<td>Adjusted\u00b9 EBITDA margin (in %) <\/td>\n<td>26.3 <\/td>\n<td>24.5 <\/td>\n<td>+ 1.8pp <\/td>\n<\/tr>\n<tr>\n<td>Group EBITDA <\/td>\n<td>35.5 <\/td>\n<td>28.9 <\/td>\n<td>+ 22.8% <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and Other Health Products <\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>adjusted\u00b9 <\/td>\n<td>34.5 <\/td>\n<td>27.3 <\/td>\n<td>+ 26.4% <\/td>\n<\/tr>\n<tr>\n<td>unadjusted <\/td>\n<td>33.8 <\/td>\n<td>27.3 <\/td>\n<td>+ 23.8% <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>2.7 <\/td>\n<td>1.6 <\/td>\n<td>+ 68.8% <\/td>\n<\/tr>\n<tr>\n<td>Reconciliation \/ Group holding <\/td>\n<td>-1.0 <\/td>\n<td>&#8211; <\/td>\n<td>&#8211; <\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin (in %) <\/td>\n<td>25.8 <\/td>\n<td>24.5 <\/td>\n<td>+ 1.3pp <\/td>\n<\/tr>\n<tr>\n<td>Branded Pharmaceuticals and  Other Health Products <\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td>adjusted\u00b9 <\/td>\n<td>43.3 <\/td>\n<td>49.1 <\/td>\n<td>&#8211; 5,8pp <\/td>\n<\/tr>\n<tr>\n<td>unadjusted <\/td>\n<td>42.4 <\/td>\n<td>49.1 <\/td>\n<td>&#8211; 6.7pp <\/td>\n<\/tr>\n<tr>\n<td>Parallel Import Business <\/td>\n<td>4.7 <\/td>\n<td>2.6 <\/td>\n<td>+ 2.1pp <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\u00b9 2018 adjusted for one-off costs in connection with the preparation of the stock exchange listing in the amount of EUR 0.7 million<\/p>\n<p>Company profile:<br \/>\nDermapharm \u2013 Pharmaceutical Excellence &#8220;Made in Germany&#8221;<br \/>\nDermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company\u2019s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 200 active pharmaceutical ingredients, which are reflected in a broad assortment of products. This assortment makes the company unique. In addition to Germany, the company\u2019s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm\u2019s business model also includes a parallel import business, which operates under the \u201caxicorp\u201d brand. Based on revenues, Dermapharm was among the top four parallel import companies in Germany in 2017. <\/p>\n<p>With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican\u00ae forte and Tromcardin\u00ae complex. <\/p>\n<p>Contact<br \/>\ncometis AG<br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: ir@dermapharm.de<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/e_180518_CN_Dermapharm_Q1_2018.pdf\" target=\"_blank\" rel=\"noopener\">Post as PDF<\/a><\/div>\n<style>\n.leseprobe-archiv {\n    color: #00225f !important;\n    border-color: #00225f;\n    position: relative;\n    padding: 0.3em 1em;\n    border: 1px solid;\n    -webkit-border-radius: 3px;\n    -moz-border-radius: 3px;\n    border-radius: 3px;\n   -webkit-transition: all 0.2s;\n    -moz-transition: all 0.2s;\n    transition: all 0.2s;\n    padding:10px;\n    width: 19%;\n    text-align: center;\n    margin-right: 10px;\n    float:left;\n}\n.leseprobe-archiv:hover {\n    background-color: #eee;\n    border-color: #ffffff;\n    cursor: pointer;\n}\n<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":54374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section admin_label=\"section\"][et_pb_row admin_label=\"Zeile\" make_fullwidth=\"off\" use_custom_width=\"off\" width_unit=\"on\" use_custom_gutter=\"off\" custom_padding=\"||0px|\" padding_mobile=\"off\" allow_player_pause=\"off\" parallax=\"off\" parallax_method=\"off\" make_equal=\"off\" parallax_1=\"off\" parallax_method_1=\"off\" parallax_2=\"off\" parallax_method_2=\"off\" column_padding_mobile=\"on\"][et_pb_column type=\"1_2\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<style>\r\n.zur\u00fcckbutton:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #00225f;\r\n    margin-right: 7px;\r\n}\r\n.zur\u00fcckbutton:hover:before {\r\n    display: inline-block;\r\n    font-family: \"ETmodules\";\r\n    content: \"4a\";\r\n    color: #d85710;\r\n    margin-right: 7px;\r\n}\r\n<\/style>\r\n<h1 style=\"text-align: justify;\">Corporate News<\/h1> <a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/veroeffentlichungsarchiv-dermapharm\">zum Archiv<\/a>\r\n\r\n[\/et_pb_text][\/et_pb_column][et_pb_column type=\"1_2\"][et_pb_image admin_label=\"Bild\" src=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png\" show_in_lightbox=\"off\" url_new_window=\"off\" use_overlay=\"off\" animation=\"off\" sticky=\"off\" align=\"right\" force_fullwidth=\"off\" always_center_on_mobile=\"on\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n\r\n\r\n[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\"row\"][et_pb_column type=\"4_4\"][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<h1>Dermapharm Holding SE ver\u00f6ffentlicht Q1-Bericht 2018<\/h1>\r\n<p><strong>\u2022 Umsatz um 16,4% auf 137,5 Mio. \u20ac gesteigert<br>\r\n\u2022 Bereinigtes EBITDA um 25,3% auf 36,2 Mio. \u20ac gestiegen, EBITDA-Marge auf 26,3% verbessert<br>\r\n\u2022 Internationale Pr\u00e4senz mit Vertriebstochter in Italien weiter ausgebaut<br>\r\n\u2022 Integration von Strathmann und Trommsdorff verl\u00e4uft planm\u00e4\u00dfig <\/strong><\/p>\r\n\r\n<p><strong>Gr\u00fcnwald, 18. Mai 2018<\/strong> \u2013 \u2013 Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete in Deutschland mit wachsender internationaler Pr\u00e4senz, ver\u00f6ffentlicht heute den Bericht \u00fcber die ersten drei Monate 2018. Das Unternehmen konnte den Umsatz im Berichtszeitraum um 16,4% auf 137,5 Mio. \u20ac steigern (Vorjahresquartal: 118,1 Mio. \u20ac). Das um Einmalkosten in H\u00f6he von 0,7 Mio. \u20ac im Zusammenhang mit der Vorbereitung der B\u00f6rsennotierung bereinigte Ergebnis vor Zinsen, Steuern und Abschreibungen (EBITDA) lag mit 36,2 Mio. \u20ac\r\num 25,3% \u00fcber dem Vorjahresquartal (28,9 Mio. \u20ac). Die bereinigte EBITDA-Marge betrug somit 26,3% und lag damit 1,8 Prozentpunkte \u00fcber der Marge des Vorjahres. Das unbereinigte EBITDA betrug 35,5 Mio. \u20ac, die unbereinigte EBITDA-Marge lag bei 25,8%.\r\nDr. Hans-Georg Feldmeier, Vorstandsvorsitzender der Dermapharm Holding SE, kommentiert: \u201eDas erste Quartal 2018 stand ganz im Zeichen unserer Drei-S\u00e4ulen-Strategie aus hauseigener Produktentwicklung, Internationalisierung und erfolgreichen Akquisitionen. Zusammen mit der Integration von Strathmann und Trommsdorff konnten wir unser Portfolio um freiverk\u00e4ufliche Topseller wie z.B. Keltican\u00ae forte, Tromcardin\u00ae complex und Ebenol\u00ae erweitern und gleichzeitig hochinteressante verschreibungspflichtige Produkte f\u00fcr unsere Kerntherapiegebiete hinzugewinnen. So st\u00e4rken wir den Anteil von Markentherapeutika am Gesamtportfolio und verringern unsere Abh\u00e4ngigkeit von direkten Krankenkassen-Rabattvertr\u00e4gen. Au\u00dferdem haben wir im ersten Quartal mit der Gr\u00fcndung der mibe pharma Italia Srl in Bozen einen wichtigen Schritt zum Ausbau unserer internationalen Pr\u00e4senz getan und den aussichtsreichen Markt Italien f\u00fcr unsere Produkte ge\u00f6ffnet.\u201c\r\n\r\nDer Umsatz im Segment \u201eMarkenarzneimittel und andere Gesundheitsprodukte\u201c konnte um 43,0% auf 79,5 Mio. \u20ac (Vorjahresquartal: 55,6 Mio. \u20ac) gesteigert werden. Die Bereinigung um die Einmalkosten im Zusammenhang mit der Vorbereitung der B\u00f6rsennotierung entf\u00e4llt vollumf\u00e4nglich auf dieses Segment. Somit erh\u00f6hte sich das bereinigte EBITDA des Segments um 26,4% auf 34,5 Mio. \u20ac, das unbereinigte EBITDA erh\u00f6hte sich um 23,8% auf 33,8 Mio. \u20ac (Vorjahresquartal: 27,3 Mio. \u20ac). Diese Steigerung ist ma\u00dfgeblich durch eine positive Entwicklung des Rohertrags bei gleichzeitiger Senkung der Aufwendung f\u00fcr Rabatte aus Direktvertr\u00e4gen mit Krankenkassen sowie der Materialkosten bedingt. Zudem wurden die Akquisitionen der Strathmann-Gruppe sowie der Trommsdorff-Gruppe erstmalig in die Konsolidierung dieses Segmentes mit einbezogen. Bedingt durch diese Erstkonsolidierung lag die bereinigte EBITDA-Marge des Segments mit 43,3% bzw. unbereinigt mit 42,4% unter der des Vorjahresquartals (49,1%). Die Integration der beiden Firmen verl\u00e4uft planm\u00e4\u00dfig und der Vorstand\r\nrechnet f\u00fcr die Zukunft mit weiteren Synergieeffekten im Konzern, die die einzelnen Margen positiv\r\nbeeinflussen werden.\r\n\r\nIm Segment \u201eParallelimportgesch\u00e4ft\u201c sank der Umsatz im Berichtszeitraum um 7,2% auf 58,0 Mio. \u20ac (Vorjahresquartal: 62,5 Mio. \u20ac). Dieser R\u00fcckgang resultierte im Wesentlichen aus der Konzentration auf margenstarke, jedoch kleinvolumige Pr\u00e4parate. Der deutsche Parallelimport-Markt wird von drei sehr gro\u00dfvolumigen Pr\u00e4paraten beherrscht, die aufgrund der derzeitigen Marktkonzentration auf wenige Gro\u00dfh\u00e4ndler in wenigen L\u00e4ndern nur sehr geringe Margen erzielen. Dermapharm hat diese Pr\u00e4parate im ersten Quartal 2018 daher nur in geringem Umfang bezogen, im Laufe des aktuellen zweiten Quartals 2018 jedoch bereits wieder mit besseren Margen durch neue Gro\u00dfh\u00e4ndler in weiteren L\u00e4ndern Europas bezogen, so dass f\u00fcr die Folgequartale wieder mit einer zunehmenden Umsatzdynamik im Parallelimportgesch\u00e4ft zu rechnen ist. Das EBITDA im Parallelimportgesch\u00e4ft konnte im ersten Quartal signifikant um 68,8% auf 2,7 Mio. \u20ac (Vorjahresquartal: 1,6 Mio. \u20ac) gesteigert werden. Dies erreichte Dermapharm durch die Optimierung des Produktportfolios, die Steigerung der Rohertragsmarge durch einen bedarfsgerechten Einkauf sowie eine stetige Kostenoptimierung in allen Bereichen. Entsprechend erh\u00f6hte sich die EBITDA-Marge im Parallelimport von 2,6% im Vorjahresquartal auf 4,7%.\r\n\r\nMit der positiven Gesch\u00e4ftsentwicklung im ersten Quartal 2018 sowie unter Annahme unver\u00e4nderter Rahmenbedingungen best\u00e4tigt der Vorstand die Gesamtjahresprognose mit einem Umsatzwachstum von 20 bis 25% und einer Verbesserung des EBITDA von 22 bis 27% im Vergleich zum Gesch\u00e4ftsjahr 2017. \r\n\r\n<strong>Finanzkennzahlen Q1 2018 im Jahresvergleich<\/strong>\r\n\r\n<table class=\"tableizer-table\">\r\n<thead><tr class=\"tableizer-firstrow\"><th>in Mio. EUR <\/th><th>Q1\/2018 <\/th><th>Q1\/2017 <\/th><th>Ver\u00e4nderung <\/th><\/tr><\/thead><tbody>\r\n <tr><td>Konzernumsatz <\/td><td>137,5 <\/td><td>118,1 <\/td><td>+ 16,4% <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><td>79,5 <\/td><td>55,6 <\/td><td>+ 43,0% <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>58,0 <\/td><td>62,5 <\/td><td>- 7,2% <\/td><\/tr>\r\n <tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>- <\/td><td>- <\/td><td>- <\/td><\/tr>\r\n <tr><td>Bereinigtes\u00b9 Konzern-EBITDA <\/td><td>36,2 <\/td><td>28,9 <\/td><td>+ 25,3% <\/td><\/tr>\r\n <tr><td>Bereinigte\u00b9 EBITDA-Marge (in %) <\/td><td>26,3 <\/td><td>24,5 <\/td><td>+ 1,8pp <\/td><\/tr>\r\n <tr><td>Konzern-EBITDA <\/td><td>35,5 <\/td><td>28,9 <\/td><td>+ 22,8% <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><\/tr>\r\n <tr><td>bereinigt\u00b9 <\/td><td>34,5 <\/td><td>27,3 <\/td><td>+ 26,4% <\/td><\/tr>\r\n <tr><td>unbereinigt <\/td><td>33,8 <\/td><td>27,3 <\/td><td>+ 23,8% <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>2,7 <\/td><td>1,6 <\/td><td>+ 68,8% <\/td><\/tr>\r\n <tr><td>\u00dcberleitung \/ Konzernholding <\/td><td>-1,0 <\/td><td>- <\/td><td>- <\/td><\/tr>\r\n <tr><td>EBITDA-Marge (in %) <\/td><td>25,8 <\/td><td>24,5 <\/td><td>+ 1,3pp <\/td><\/tr>\r\n <tr><td>Markenarzneimittel und andere Gesundheitsprodukte <\/td><\/tr>\r\n <tr><td>bereinigt\u00b9 <\/td><td>43,3 <\/td><td>49,1 <\/td><td>- 5,8pp <\/td><\/tr>\r\n <tr><td>unbereinigt <\/td><td>42,4 <\/td><td>49,1 <\/td><td>- 6,7pp <\/td><\/tr>\r\n <tr><td>Parallelimportgesch\u00e4ft <\/td><td>4,7 <\/td><td>2,6 <\/td><td>+ 2,1pp <\/td><\/tr>\r\n<\/tbody><\/table>\r\n\r\n\u00b9 2018 bereinigt um Einmalkosten im Zusammenhang mit der Vorbereitung der B\u00f6rsennotierung i.H.v. 0,7 Mio. EUR\r\n\r\n<strong>Unternehmensprofil:\r\nDermapharm - Pharmazeutische Exzellenz \"Made in Germany\"<\/strong>\r\nDermapharm ist ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte M\u00e4rkte in Deutschland. Die 1991 gegr\u00fcndete Gesellschaft hat ihren Sitz in Gr\u00fcnwald bei M\u00fcnchen und ihren Hauptproduktionsstandort in Brehna bei Leipzig. Das integrierte Gesch\u00e4ftsmodell der Gesellschaft umfasst die hausinterne Entwicklung, eigene Produktion sowie den Vertrieb von Arzneimitteln und anderen Gesundheitsprodukten f\u00fcr ausgew\u00e4hlte M\u00e4rkte durch einen pharmazeutisch geschulten Au\u00dfendienst. Dermapharm verf\u00fcgt \u00fcber rund 900 Arzneimittelzulassungen f\u00fcr mehr als 200 pharmazeutische Wirkstoffe, die sich in einem breiten Produktsortiment widerspiegeln. Dieses Sortiment macht das Unternehmen unverwechselbar. Zu den Kernm\u00e4rkten der Gesellschaft geh\u00f6ren derzeit neben Deutschland auch \u00d6sterreich und die Schweiz. Die Gesellschaft plant, ihre internationale Pr\u00e4senz weiter auszubauen. Das Gesch\u00e4ftsmodell von Dermapharm umfasst \u00fcberdies ein Parallelimportgesch\u00e4ft, das unter der Marke \u201eaxicorp\u201c betrieben wird. Ausgehend vom Umsatz geh\u00f6rte Dermapharm hier 2017 zu den vier umsatzst\u00e4rksten Parallelimporteuren in Deutschland.\r\n\r\nMit einer konsequenten F&E-Strategie und zahlreichen erfolgreichen Produkt- und Firmen\u00fcbernahmen in den vergangenen 25 Jahren hat Dermapharm ihre Gesch\u00e4ftsaktivit\u00e4ten kontinuierlich optimiert und neben organischem Wachstum f\u00fcr externe Wachstumsimpulse gesorgt. Diesen profitablen Wachstumskurs beabsichtigt Dermapharm auch in Zukunft fortzuf\u00fchren. Dabei setzt das Unternehmen auf drei Wachstumstreiber: die hausinterne Entwicklung neuer Produkte, die Ausweitung der internationalen Pr\u00e4senz sowie weitere Akquisitionen. Dazu z\u00e4hlt der Erwerb des Arzneimittelherstellers und \u2013vermarkters Trommsdorff im Januar 2018, zu dessen Portfolio beispielsweise die bekannten Marken Keltican\u00ae forte und Tromcardin\u00ae complex geh\u00f6ren.\r\n\r\n<strong>Kontakt<\/strong>\r\ncometis AG\r\nClaudius Krause\r\nTel.: +49 (0)611 \u2013 205855-28\r\nFax: +49 (0)611 \u2013 205855-66\r\nE-Mail: ir@dermapharm.de\r\n\r\n[\/et_pb_text][et_pb_text admin_label=\"Text\" background_layout=\"light\" text_orientation=\"left\" use_border_color=\"off\" border_color=\"#ffffff\" border_style=\"solid\"]\r\n\r\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/ir.dermapharm.de\/pdf\/d_180518_CN_Dermapharm_Q1_2018.pdf\" target=\"_blank\">Beitrag als PDF<\/a><\/div>\r\n<style>\r\n.leseprobe-archiv {\r\n    color: #00225f !important;\r\n    border-color: #00225f;\r\n    position: relative;\r\n    padding: 0.3em 1em;\r\n    border: 1px solid;\r\n    -webkit-border-radius: 3px;\r\n    -moz-border-radius: 3px;\r\n    border-radius: 3px;\r\n   -webkit-transition: all 0.2s;\r\n    -moz-transition: all 0.2s;\r\n    transition: all 0.2s;\r\n    padding:10px;\r\n    width: 19%;\r\n    text-align: center;\r\n    margin-right: 10px;\r\n    float:left;\r\n}\r\n.leseprobe-archiv:hover {\r\n    background-color: #eee;\r\n    border-color: #ffffff;\r\n    cursor: pointer;\r\n}\r\n<\/style>\r\n\r\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[326,448],"tags":[489],"class_list":["post-19294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-489"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-18T08:46:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:50:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"172\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report\",\"datePublished\":\"2018-05-18T08:46:51+00:00\",\"dateModified\":\"2022-03-10T04:50:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\"},\"wordCount\":1255,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2018\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\",\"name\":\"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2018-05-18T08:46:51+00:00\",\"dateModified\":\"2022-03-10T04:50:54+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"width\":172,\"height\":174,\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG","og_description":"Corporate news to the archive Dermapharm Holding SE publishes Q1 2018 report Revenues increased by 16.4% to EUR 137.5 million Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to 26.3% International presence continued to expand with sales subsidiary in Italy Integration of Strathmann and Trommsdorff on schedule Gr\u00fcnwald, May 18, 2018 [&hellip;]","og_url":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/","og_site_name":"cometis AG","article_published_time":"2018-05-18T08:46:51+00:00","article_modified_time":"2022-03-10T04:50:54+00:00","og_image":[{"width":172,"height":174,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report","datePublished":"2018-05-18T08:46:51+00:00","dateModified":"2022-03-10T04:50:54+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/"},"wordCount":1255,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2018"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/","url":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/","name":"May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2018-05-18T08:46:51+00:00","dateModified":"2022-03-10T04:50:54+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/18-mai-2018-dermapharm-holding-se-veroeffentlicht-q1-bericht-2018\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":172,"height":174,"caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=19294"}],"version-history":[{"count":0,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/19294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/54374"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=19294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=19294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=19294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}